NO990433L - Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet - Google Patents

Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet

Info

Publication number
NO990433L
NO990433L NO990433A NO990433A NO990433L NO 990433 L NO990433 L NO 990433L NO 990433 A NO990433 A NO 990433A NO 990433 A NO990433 A NO 990433A NO 990433 L NO990433 L NO 990433L
Authority
NO
Norway
Prior art keywords
compositions
treatment
diseases associated
new compounds
tryptase activity
Prior art date
Application number
NO990433A
Other languages
English (en)
Other versions
NO990433D0 (no
Inventor
Jeffrey Mark Dener
Elaine Yee-Lin Kuo
Ken Duane Rice
Vivian Rueywen Wang
Wendy Beth Young
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of NO990433D0 publication Critical patent/NO990433D0/no
Publication of NO990433L publication Critical patent/NO990433L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår nye forbindelser som er tryptaseinhibitorer; deres farmasøytisk akseptable salter og N-oksider; deres anvendelse som terapeutiske midler, samt fremgangsmåter for deres fremstilling.
NO990433A 1996-07-30 1999-01-29 Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet NO990433L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US89577297A 1997-07-17 1997-07-17
PCT/US1997/013422 WO1998004537A1 (en) 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity

Publications (2)

Publication Number Publication Date
NO990433D0 NO990433D0 (no) 1999-01-29
NO990433L true NO990433L (no) 1999-03-25

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990433A NO990433L (no) 1996-07-30 1999-01-29 Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet

Country Status (17)

Country Link
EP (1) EP0934293A1 (no)
JP (1) JP2001509787A (no)
KR (1) KR20000029679A (no)
CN (1) CN1073103C (no)
AU (1) AU733621B2 (no)
CA (1) CA2262542A1 (no)
CZ (1) CZ29799A3 (no)
EE (1) EE9900036A (no)
FI (1) FI990171A7 (no)
HU (1) HUP0003267A3 (no)
LV (1) LV12291B (no)
NO (1) NO990433L (no)
NZ (1) NZ333713A (no)
PL (1) PL331465A1 (no)
SI (1) SI9720047A (no)
SK (1) SK8599A3 (no)
WO (1) WO1998004537A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
ES2233025T3 (es) * 1998-02-06 2005-06-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Agente inhibidores de la triptasa.
US6613769B1 (en) * 1998-02-06 2003-09-02 Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. Tryptase inhibitors
JP2003524598A (ja) * 1998-09-04 2003-08-19 アルタナ ファルマ アクチエンゲゼルシャフト 新規ピラノセン
EP1208089B1 (en) 1999-08-10 2004-10-13 ALTANA Pharma AG Diazocin-dione derivatives and their use as tryptase inhibitors
US6960588B1 (en) 1999-09-14 2005-11-01 Altana Pharma Ag Tryptase inhibitors
AU1413301A (en) * 1999-11-17 2001-05-30 Sumitomo Pharmaceuticals Company, Limited Diabetic remedy containing dipiperazine derivative
DE19955476A1 (de) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2222259T3 (es) * 1999-12-20 2005-02-01 Altana Pharma Ag Inhibidores de triptasa.
CA2392127A1 (en) 1999-12-20 2001-06-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
EP1358182B1 (en) * 2001-01-31 2004-08-11 ALTANA Pharma AG Diazocine derivatives and their use as tryptase inhibitors
WO2002066430A1 (en) 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
JP2004518735A (ja) 2001-02-21 2004-06-24 アルタナ　ファルマ　アクチエンゲゼルシャフト トリプターゼインヒビター
EP1370518A2 (en) * 2001-03-15 2003-12-17 ALTANA Pharma AG Tryptase-inhibitors
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2002100347A2 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6962941B2 (en) 2001-06-19 2005-11-08 Altana Pharma Ag Tryptase inhibitors
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
MX2011006353A (es) 2008-12-19 2011-07-13 Merz Pharma Gmbh & Co Kgaa Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos.
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
FR3038605B1 (fr) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
WO2018207950A1 (ja) * 2017-05-12 2018-11-15 横山　茂之 クラスａ ｇｐｃｒ結合性化合物改変体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
SK282537B6 (sk) * 1993-03-12 2002-10-08 Axys Pharmaceuticals, Inc. Inhibítor tryptázy alebo jeho farmaceuticky prijateľná soľ, farmaceutický prostriedok s jeho obsahom a jeho použitie
US5656660A (en) * 1994-06-01 1997-08-12 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
SK37997A3 (en) * 1994-09-23 1998-12-02 Arris Pharm Corp Compositions and methods for treating mast-cell inflammatory condition
JPH11503417A (ja) * 1995-03-24 1999-03-26 アリス・ファーマシューティカル・コーポレイション 可逆的プロテアーゼインヒビター
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
FI990171L (fi) 1999-03-23
LV12291A (lv) 1999-06-20
CZ29799A3 (cs) 1999-06-16
AU733621B2 (en) 2001-05-17
FI990171A7 (fi) 1999-03-23
SK8599A3 (en) 2000-03-13
CN1073103C (zh) 2001-10-17
CA2262542A1 (en) 1998-02-05
FI990171A0 (fi) 1999-01-29
HUP0003267A3 (en) 2002-02-28
CN1226892A (zh) 1999-08-25
EE9900036A (et) 1999-08-16
WO1998004537A1 (en) 1998-02-05
SI9720047A (sl) 1999-08-31
JP2001509787A (ja) 2001-07-24
NO990433D0 (no) 1999-01-29
KR20000029679A (ko) 2000-05-25
NZ333713A (en) 2000-12-22
EP0934293A1 (en) 1999-08-11
PL331465A1 (en) 1999-07-19
HUP0003267A2 (hu) 2001-06-28
AU3967097A (en) 1998-02-20
LV12291B (en) 2000-04-20

Similar Documents

Publication Publication Date Title
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
NO20012977D0 (no) N-ureidoalkylpiperidiner som modulatorer av chemokinreseptoraktivitet
SE0202462D0 (sv) Novel use
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
NO992400L (no) Nye substituerte pyrazolderivater
NO991732L (no) Nye heterocyklylmetylsubstituerte pyrazolderivater
ATE302606T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR0313407A (pt) Novo uso de derivados de benzotiazol
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
NO20014529D0 (no) Tetrahydropyranderivater og deres anvendelse som terapautiske midler
NO20073113L (no) Indenylderivater og anvendelse derav for behandling av neurologiske lidelser
DK0888271T3 (da) Benzamidinderivater substitueret med aminosyre- og hydroxysyrederivater og deres anvendelse som antikoagulerende midler
NO20016201L (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
ATE251139T1 (de) (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten
DE60031686D1 (de) Pyrazinone, diese verbindungen enthaltende zusammenstellungen
BR0317289A (pt) Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico
NO982863L (no) Nye forbindelser med analgetisk effekt
DK0871446T3 (da) Anvendelse af eliprodil til fremstilling af et lægemiddel til behandling af ischaemiske sygdomme i nethinden eller den optiske nerve
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
DK0767783T3 (da) Substituerede alkyldiaminderivater og deres anvendelse som tachykinin-antagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application